IL6 and COVID-19: In a situation representative of severe COVID-19 (3 ng/ml IL-6 in BAF; mAb penetration into BAF 10% of that in plasma), a single injection of siltuximab inhibited IL-6 bioactivity by 90%, with an immediate resumption of IL-6 bioactivity within 24 hours (Supplementary Figure 2A).